Abstract
More than 1.2 million percutaneous coronary interventions are performed annually in the United States, with only an estimated 33% performed in women, despite the established benefits of percutaneous coronary intervention and adjunctive pharmacotherapy in reducing fatal and nonfatal ischemic complications in acute myocardial infarction and high-risk acute coronary syndromes. This statement reviews sex-specific data on the safety and efficacy of contemporary interventional therapies in women.
MeSH terms
-
Angioplasty, Balloon, Coronary / methods*
-
Angioplasty, Balloon, Coronary / mortality
-
Angioplasty, Balloon, Coronary / statistics & numerical data
-
Coronary Disease / mortality
-
Coronary Disease / therapy*
-
Drug Therapy / methods*
-
Drug Therapy / statistics & numerical data
-
Female
-
Fibrinolytic Agents / administration & dosage
-
Fibrinolytic Agents / pharmacology
-
Fibrinolytic Agents / therapeutic use
-
Humans
-
Platelet Aggregation Inhibitors / administration & dosage
-
Platelet Aggregation Inhibitors / pharmacology
-
Platelet Aggregation Inhibitors / therapeutic use
-
Sex Factors
-
Stents / adverse effects
-
Treatment Outcome
Substances
-
Fibrinolytic Agents
-
Platelet Aggregation Inhibitors